Search

Puma Biotechnology Inc

Cerrado

SectorSanidad

8.82 1.73

Resumen

Variación precio

24h

Actual

Mínimo

8.61

Máximo

8.93

Métricas clave

By Trading Economics

Ingresos

12M

8.2M

Ventas

12M

57M

P/B

Media del Sector

17.38

57.002

BPA

0.16

Margen de beneficios

14.493

Empleados

179

EBITDA

14M

14M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-32.58% downside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

45M

449M

Apertura anterior

7.09

Cierre anterior

8.82

Noticias sobre sentimiento de mercado

By Acuity

26%

74%

77 / 340 Clasificación en Healthcare

Puma Biotechnology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ago 2026, 19:26 UTC

Puma Biotechnology Inc shares are lower today, following an early peak. Broader market data showed rising jobless claims and flat producer price index growth.

12 ago 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher today, supported by positive market sentiment following a favorable inflation report. Earlier, shares pulled back from session highs.

11 ago 2026, 22:01 UTC

Puma Biotechnology Inc shares declined in after-market trading, continuing a downward trend since Tuesday's close, amid no specific news to explain the movement.

10 ago 2026, 20:06 UTC

Puma Biotechnology Inc. shares are lower today, reflecting broader market trends amid an unexpected decline in U.S. jobs and inflation reassessments.

7 ago 2026, 20:02 UTC

News

Puma Biotechnology shares rise following strong earnings and TD Cowen's price target increase to $6.00. Trading volume indicates heightened investor interest.

6 ago 2026, 19:26 UTC

Puma Biotechnology Inc shares are higher Thursday, maintaining upward momentum after three consecutive gains, despite a pullback earlier in the session.

5 ago 2026, 21:51 UTC

News

Puma Biotechnology shares are trading lower in after-market hours following the grant of stock awards to new employees, which may dilute existing shareholder value.

4 ago 2026, 19:56 UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

3 ago 2026, 19:51 UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

31 jul 2026, 19:16 UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

30 jul 2026, 18:31 UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

29 jul 2026, 18:23 UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

28 jul 2026, 18:06 UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

27 jul 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher, reflecting broader market gains amid a significant decline in crude oil prices following geopolitical developments.

24 jul 2026, 19:26 UTC

Puma Biotechnology Inc. shares are roughly flat as no specific news emerged during Friday's trading session, fluctuating within a routine range.

23 jul 2026, 20:06 UTC

Puma Biotechnology Inc shares are higher during Thursday's session, continuing an upward trend since Wednesday's close amid no specific news identified.

22 jul 2026, 22:51 UTC

Puma Biotechnology Inc shares are trading higher in after-market hours, building on earlier gains. The stock remains above its 20-day moving average.

21 jul 2026, 18:02 UTC

Puma Biotechnology Inc shares are higher during Tuesday's session, continuing a positive trend since Monday. The stock remains above its 20-day moving average.

20 jul 2026, 20:06 UTC

Puma Biotechnology Inc shares are lower today, having reached a mid-day low of -4.46%. No specific news has been identified to explain the decline.

Comparación entre iguales

Cambio de precio

Puma Biotechnology Inc previsión

Precio Objetivo

By TipRanks

-32.58% descenso

Estimación a 12 Meses

Media 6 USD  -32.58%

Máximo 6 USD

Mínimo 6 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Puma Biotechnology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

0

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

77 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat